ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

Surgeon General plans new report, database, on tobacco.

January 16, 2004

NCI Committee Attempts To Redesign Cooperative Groups Without Doing Harm

June 12, 1998

National Cancer Act: Early Promises Were Overstated

May 15, 1998

In Brief: ACR to Move From Chicago To Washington D.C. Area; Hanks Astro President, Phillips President Elect

December 16, 1983

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990